Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation

Atención a la conclusión: 

"Switching INR-guided VKA treatment to a NOAC in frail older patients with AF was associated with more bleeding complications compared to continuing VKA treatment, without an associated reduction in thromboembolic complications."

https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066485?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Como podeis observar incrementa el riesgo en pacientes fragiles el pasar de los antivitamina K a los NACOS.

Enviado desde mi iPhone